



Pharmaceutical POOL

Dr. Julie **GERBERDING**

Dr. Michael **ROSENBLATT**

Former CDC Head Joins Merck Vaccines



Merck has announced two changes to its leadership team. The global pharmaceutical company has appointed former Centers for Disease Control and Prevention (CDC) Director Julie Gerberding, M.D., president of Merck Vaccines. Dr. Gerberding led the CDC as director from 2002 to 2009.



Dr. Gerberding has an M.D. from Case Western Reserve University and an MPH from the University of California, Berkeley.

In other moves, Merck has named former Tufts University School of Medicine Dean Michael Rosenblatt, M.D., executive VP and chief medical officer. Dr. Rosenblatt leads Merck's Global Center for Scientific Affairs and serves as the company's primary voice to the global medical community.

Dr. Rosenblatt earned an M.D. magna cum laude from Harvard Medical School and received endocrinology training at Massachusetts General Hospital.

Sean **NOLAN**

Lundbeck Taps U.S. CEO

Denmark-based international pharmaceutical firm H. Lundbeck A/S has named Sean Nolan CEO of its U.S. business, Lundbeck Inc., formed in the wake of Lundbeck's March



2009 acquisition of Ovation Pharmaceuticals. Mr. Nolan succeeds Ovation founder Jeffrey Aronin, who continues as a strategic advisor to Lundbeck Inc. Mr. Nolan has been with

Lundbeck for more than five years in a variety of roles, most recently serving as chief commercial officer.

Derica **RICE**

Lilly CFO Assumes Additional Role



Derica Rice, senior VP and chief financial officer for Lilly, has been promoted to executive VP, global services and chief financial officer. Mr. Rice's expanded role includes responsibility for global

services, including the ongoing global services design project, as well as IT and Six Sigma. He received an MBA from Indiana University.

Biotechnology POOL

Hans **BISHOP**

Dendreon Adds Operating Chief



Hans Bishop has joined Dendreon as chief operating officer as the biotechnology company prepares for the launch of Provenge, an immunotherapy in late-stage development for metastatic,

androgen-independent prostate cancer. Mr. Bishop's responsibilities at Dendreon include sales and marketing, as well as manufacturing, supply chain, quality, and facilities engineering. He previously served as president of the specialty medicine business at Bayer.

Dr. Thomas **HOFSTAETTER**

Former Wyeth Executive Joins VaxInnate



VaxInnate, a privately held biotechnology company focused on developing novel vaccines, has named Thomas Hofstaetter, Ph.D., chief operating officer, with responsibility for business

development, finance, and human resources.

Dr. Hofstaetter was most recently senior VP of corporate business development for Wyeth and head of global business development for Wyeth's pharmaceutical division. A biochemist by training, Dr. Hofstaetter received both an M.S. in biochemistry and a Ph.D. magna cum laude in molecular biology from Universität Tübingen in Tübingen, Germany.

Nancy **WYSENSKI**

Vertex Appoints Chief Commercial Officer



Vertex Pharmaceuticals has named Nancy Wysenski executive VP and chief commercial officer amid the biotechnology company's preparations for the potential launch of its late-stage product candidates. Ms. Wysenski has broad responsibility for sales, marketing, market research, and sales operations activities.


Ms. Wysenski was most recently chief operating officer at Endo Pharmaceuticals. She holds an executive MBA from Baldwin-Wallace College.

Biopharmaceutical POOL

Dr. Kenneth **ATTIE**

Melissa **MORANDI**

Accelaron Creates Positions



Accelaron Pharma, a privately held biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues, has created two key positions to expand its management team.

Kenneth Attie, M.D., has joined Accelaron as VP of medical research. Dr. Attie was previously VP of clinical development and medical affairs for Altus Pharma-

ceuticals. He received an M.D. from New York University Medical Center.



Acceleron has appointed Melissa Morandi VP of quality. Before joining Acceleron, Ms. Morandi held the same position at Anesiva. She is regulatory affairs certified (RAC) and has an M.S. in

immunology from California State University, Northridge.

Dr. Stephen DOBERSTEIN

Dr. Lorianne MASUOKA

Nektar Therapeutics Makes Leadership Shifts



Nektar Therapeutics, a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms, has appointed Stephen Doberstein, Ph.D., to the newly created position of senior VP and chief scientific officer, with responsibility for leading all aspects of discovery research.



Dr. Doberstein was most recently VP of research at Xoma. He received a Ph.D. in biochemistry, cell, and molecular biology from The Johns Hopkins University School of Medicine and completed his post-doctoral work at the University of California, Berkeley.

Nektar also has announced the promotion of Lorianne Masuoka, M.D., to senior VP and chief medical officer from her previous role as chief medical officer. Dr. Masuoka continues to lead clinical development, regulatory affairs, drug safety, clinical pharmacology, toxicology, and program management for Nektar.

She received an M.D. from the University of California, Davis, completed a fellowship at Yale University, and is board-certified in neurology.

Specialty POOL

Andrew PANAGY

Noven Pharmaceuticals Selects Marketing VP

Privately held specialty company Noven Pharmaceuticals has named Andrew Panagy VP of marketing and sales, with responsibility for all marketing and sales activities at both



Noven Therapeutics and Novogyne Pharmaceuticals, Noven's joint venture with Novartis Pharmaceuticals.

Before joining Noven, he was VP and global business manager of Wyeth Pharmaceuticals' Women's Health Care business unit.

Noven's business and operations are focused in three principal areas: transdermal drug delivery; the Novogyne joint venture; and Noven Therapeutics, Noven's specialty pharmaceutical unit.

Device/Diagnostic POOL

Dr. Jonathan KNOWLES

Roche Executive Joins Caris Diagnostics



Caris Diagnostics (Caris Dx), a provider of integrated anatomic pathology and oncology testing services, has appointed Jonathan Knowles, Ph.D., vice chairman.

Dr. Knowles provides Caris Dx with scientific and strategic guidance, supports the identification and expansion of R&D opportunities, and assists with the development of Caris Dx's international presence.

Dr. Knowles was most recently president of group research at Roche. He received a Ph.D. in genetics of mitochondria from the University of Edinburgh.

Dr. Gary PALMER

On-Q-ity Appoints Medical Chief



On-Q-ity, a next-generation oncology diagnostics company developing products to improve cancer therapy effectiveness, has appointed Gary Palmer, M.D., J.D., MBA, MPH, chief medical officer. Dr. Palmer is responsible for driving the clinical development and physician education and adoption of On-Q-ity's novel predictive biomarker and circulating tumor cell (CTC) diagnostic products.

Dr. Palmer was previously VP of Medical Affairs at Genomic Health. A medical oncologist, Dr. Palmer received an M.D. from Stanford University School of Medicine; an MBA from the University of California, Davis; an MPH from the University of California, Los Angeles; and a law degree from Concord University.

Emerging POOL

Dr. David CLARK

Dr. Martin TOLAR

NormOxys Expands Leadership Team

NormOxys, a biotechnology company developing a novel class of small molecule drugs that enhance the body's ability to deliver oxygen to diseased tissues, has added industry veterans to its executive leadership. David Clark, M.D., has joined NormOxys as the company's first chief medical officer. In this role, Dr. Clark manages NormOxys' clinical affairs, including the development of its lead product candidate.

Before joining NormOxys, Dr. Clark spent almost a decade with Pfizer, leading clinical teams while working in the company's clinical development division. He earned an M.D. from the University of Edinburgh Medical School.



In other moves, NormOxys has appointed recognized neuroscience expert and seasoned drug development executive Martin Tolar, M.D., Ph.D., president and CEO.

Dr. Tolar has held senior positions in pharmaceutical and biotechnology industries, as well as academia. Most recently, he was executive VP and chief business officer for CoMentis. He received a Ph.D. in neuroscience.

Frank JACOBUCCI

Access Pharmaceuticals Appoints VP



Access Pharmaceuticals, an emerging biopharmaceutical company that develops and commercializes products for the treatment and supportive care of cancer patients, has named Frank Jacobucci VP, sales and marketing.

In this role, Mr. Jacobucci has primary responsibility for the company's 2010 marketing launch of MuGard, an FDA-approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

Adelene PERKINS

Infinity Pharmaceuticals Appoints CEO

Adelene Perkins has become president and



CEO of Infinity Pharmaceuticals in accordance with an existing management succession plan. Ms. Perkins succeeds Infinity founder Steven Holtzman, who remains executive chair of the company's board. Ms. Perkins holds an MBA from Harvard Business School.

William **SIBOLD**

Lycera Selects CEO



Lycera, an emerging pharmaceutical company focused on developing novel small-molecule medicines to treat autoimmune diseases, has named William Sibold president and CEO.

Mr. Sibold was previously senior VP, U.S. commercial for Biogen Idec. He earned an MBA from Harvard Business School.

Agency **POOL**

Susan **CHOUHDY**

Bob **DEBARTOLO**

Scott **FANELLI**

Goble & Associates Expands Staff



Goble & Associates (G&A) has announced the addition of two account directors and a senior strategy director to its team.

Susan Chouhdry has joined G&A as account director. Ms. Chouhdry was most recently with Williams-Labadie.



Bob DeBartolo has been named senior director, integrated strategy. Mr. DeBartolo was most recently VP, client engagements, for Cadient Group.



Scott Fanelli has been appointed group account director. Mr. Fanelli was previously a group account supervisor at Corbett Accel Healthcare Group.

Susan **JOHNSON**

PSSG Promotes Client Services VP

Publicis Strategic Solutions Group (PSSG), a provider of multichannel message delivery



solutions for the life-sciences industry, has named Susan Johnson VP of client services for Publicis Selling Solutions, Arista Marketing Associates, and Pharmagistics. PSSG is a division of Publicis Healthcare Communications Group.

Most recently, she served as senior director of business development for Publicis Selling Solutions.

Barry **WINN**

New Business Development VP at Cadient



Cadient Group, a strategic interactive marketing agency serving the healthcare industry, has named Barry Winn VP of business development. Mr. Winn is responsible for generating new business. Before joining Cadient, Mr. Winn served as director of client services and digital strategy for The Hal Lewis Group.

Consulting **POOL**

Dr. Vicky **HINES**

Walter **HOUSEMAN**

Halloran Consulting Expands Team



Halloran Consulting Group (HCG), a firm that specializes in clinical development strategy and services for established and emerging life-sciences companies, has appointed Vicky Hines, Ph.D., as a principal consultant.



Dr. Hines was most recently therapeutic director at Celtic Pharma, a healthcare-focused private equity fund. She holds a Ph.D. in biochemistry from the University of Chicago.

HCG has named Walter Houseman a consultant. Mr. Houseman joins HCG from CRF Health, where he was VP of operations.

Suzanne **HOLTER**

Bill **TRUHE**

Quintiles Makes Appointments in Consulting Group

Quintiles has added two executives to its



consulting practice. As change management practice leader, Suzanne Holter is building a change management service to help clients effect smooth business transformations.

Before joining Quintiles, Ms. Holter was a leader in BearingPoint's human capital and strategic change practice. She received an MBA in strategy from the Carlson School of Management at the University of Minnesota.

Bill Truhe has been appointed pharmacovigilance solutions leader, with responsibility for building a drug safety consulting service practice at Quintiles.



Mr. Truhe was previously VP, safety data management and quality systems for Johnson & Johnson, as well as a board member of the company's benefit risk management (BRM) global pharmacovigilance organization. He received an MBA from Lehigh University.

Mario **NACINOVICH JR.**

Axon Strengthens U.S. Market Presence



Axon has extended its operations in the United States with the appointment of Mario Nacinovich Jr. as managing director of Axon US, based in New York. Axon is a specialist healthcare consulting firm and the international healthcare operation of National Public Relations, one of the world's largest independent communications firms.

Mr. Nacinovich joins Axon from QD Healthcare Group, where he was most recently VP of strategic planning and business development.

CRO **POOL**

Stephen **KASAY**

PharmaNet Selects Chief Information Officer



PharmaNet Development Group, a provider of clinical development services to pharmaceutical, biotechnology, generic drug, and medical device companies, has appointed Stephen Kasay chief information officer. Mr. Kasay has global responsibility for PharmaNet's corporate information technology function.

Dr. Sharon MOORE

Chiltern Promotes U.S.-Based Executive



London-based CRO Chiltern International has promoted Sharon Moore, M.D., to executive VP, global quality and medical affairs, based at Chiltern's U.S. office in Bristol, Tenn.

A physician with 15 years of industry experience, Dr. Moore has been with Chiltern since the company's acquisition of CTMS, a U.S. CRO, in 2007.

Dr. Moore earned an MBA from East Tennessee State University, an M.D. from Vanderbilt University School of Medicine, and an MPH in general preventive medicine and public health from the Medical College of Wisconsin.

Service POOL**Nikki BONNELL****Susan JALBERT****Dr. Albert RAMON**

Unithink Makes U.S. Appointments



Unithink, which provides electronic data capturing solutions and services to the healthcare industry, has promoted Nikki Bonnell to head of U.S. operations.



Susan Jalbert has been named VP, U.S. sales. She has held senior positions at Medidata Solutions, Relsys International, and Domain Pharma (now Phase Forward).



Albert Ramon, M.D., Ph.D., has been appointed chief scientific officer. Previously, he was a staff member at the University Hospital of Antwerp, Belgium, department of gastroenterohepatology. Dr. Ramon has a European doctor certificate in immunology and a master's in business administration.

Dr. Raymond FABIUS

Thomson Reuters Selects Medical Chief

Raymond Fabius, M.D., FAAP, FACPE,



has joined Thomson Reuters as chief medical officer of the company's healthcare and science business.

Dr. Fabius is responsible for developing and deepening relationships with customers.

Most recently, Dr. Fabius was strategic advisor to the president of Walgreens Health & Wellness division.

He received an M.D. from Hahnemann Medical College (now the Drexel College of Medicine) and is board certified in pediatrics and medical management.

Leanne LARSON

Outcome Sciences Hires Development VP



Outcome Sciences, a provider of patient registries, studies, and technologies for evaluating real-world outcomes, has appointed Leanne Larson, MHA, VP, strategic development.

Ms. Larson was most recently VP for Sg2 Healthcare Intelligence. She received an MHA from Governors State University.

Marianne McGowan**NUGENT**

Publicis Selling Solutions Appoints VP



Publicis Selling Solutions, a provider of sales, service, and clinical teams for the biopharma industry, has named Marianne McGowan Nugent VP of sales training.

Ms. Nugent has been with Publicis Selling Solutions for more than three years, most recently serving as VP of sales operations and client services. Publicis Selling Solutions is a division of Publicis Strategic Solutions Group.

John SORY

ERT Adds Healthcare Solutions VP



ERT, a provider of centralized services to the biopharmaceutical, medical-device, and related industries, has appointed John Sory to the newly created role of senior VP of healthcare solutions.

He joins ERT following a 16-year career at Pfizer, most recently as VP and general manager of Pfizer Health Solutions.

Dennis TOUSSAINT

Prosar Adds Device Safety Director



Prosar, a provider of adverse event processing and medical information services, has hired Dennis Toussaint, M.S., as director, medical device safety. Mr. Toussaint most recently was director, regulatory affairs for SterilMed.

Technology POOL**Dr. Paul BURRIN**

Accelrys Names Marketing Chief



Accelrys, a provider of scientific business intelligence software and services for the life-sciences industry, has appointed Paul Burrin, Ph.D., senior VP and chief marketing officer. Dr. Burrin joins

Accelrys from Google. He received a Ph.D. in earth science from the London School of Economics at the University of London.

Tom HERNANDEZ

Take Supply Chain Hires Sales VP



Take Supply Chain, a provider of software solutions to power demand-driven value networks, has named Tom Hernandez executive VP of worldwide sales. He was VP, enterprise asset management for Infor-SSA.

Michael OWINGS

Phase Forward Hires Privacy Officer



Phase Forward, a provider of data management solutions for clinical trials and drug safety, has named Michael Owings to the newly created role of chief privacy officer. Mr. Owings is responsible for all privacy and data protection policies and best practices. ♦

Send your personnel announcements to feedback@pharmavoices.com.

SEE DIGITAL EDITION FOR BONUS CONTENT
WWW.PHARMAVOICE.COM

TALENT pool

Pharmaceutical **POOL**John **DUCKER**

Leadership Transition at APP Pharmaceuticals

John Ducker has been named to succeed retiring APP Pharmaceuticals President and CEO Thomas Silberg. Under the succession plan, Mr. Silberg is serving as a consultant to APP during 2010 to ensure a smooth transition as Mr. Ducker assumes his new responsibilities.

Mr. Ducker was previously a member of the management board of Fresenius Kabi, the parent company of APP Pharmaceuticals, and was responsible for the Fresenius Kabi Innovation Centre. He holds a master's degree in chemical engineering from Cambridge University.

APP Pharmaceuticals is a fully integrated pharmaceutical company that develops, manufactures, and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic, and critical care markets.

Biotechnology **POOL**Dr. Mark **BAGARAZZI**

Former Merck Executive Joins Inovio Biomedical

Inovio Biomedical, a company focused on DNA vaccine design, development, and delivery, has appointed DNA vaccines expert Mark Bagarazzi, M.D., chief medical officer. Dr. Bagarazzi leads worldwide clinical development and regulatory activities for Inovio's next-generation vaccines for the treatment and prevention of influenza, HIV, other infectious diseases, as well as various cancers.

Dr. Bagarazzi was most recently Merck's director of worldwide regulatory affairs for vaccines and biologics. He holds several patents and has co-authored dozens of scientific papers on the subject of DNA vaccines that have been published in peer-reviewed medical journals. Dr. Bagarazzi received an M.D. with honors from the University of Medicine and Dentistry of New Jersey.

Suzanne **CADDEN**

ImmunoGen Names Regulatory VP

ImmunoGen, a biotechnology company

that develops targeted anticancer products, has appointed Suzanne Cadden VP of regulatory affairs and quality. Ms. Cadden's responsibilities include establishing, in conjunction with the chief medical officer, the registration strategy for ImmunoGen's product candidates, as well as directing the development of regulatory submissions. Ms. Cadden has more than two decades of experience at both pharmaceutical and biotechnology companies. Before joining ImmunoGen, she was VP of regulatory affairs and clinical development at Sierra Neuropharmaceuticals. She received an M.Sc. in pharmacology from the University of Western Ontario.

Dr. Rahul **JASUJA**

Idera Pharmaceuticals Appoints Corporate Development VP

Idera Pharmaceuticals, a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLR), has appointed Rahul Jasuja, Ph.D., VP of corporate development.

Dr. Jasuja previously served as managing director, life-sciences investment banking, at MDB Capital Group. He received a Ph.D. in immunology from Tufts University School of Medicine and carried out his postdoctoral training at Harvard Medical School.

Agency **POOL**Zeynep **BEYLI**Anne Schutte **LANGE**

HLG Makes Account Team Shifts

The Hal Lewis Group (HLG), a branding agency focused on strategic marketing and advertising services for companies in the healthcare sector, has hired Zeynep Beyli as an account executive. Mr. Beyli is fluent in both German and Turkish and brings to HLG diverse client experience with a strong focus in the consumer sector.

HLG also has announced the promotion of Anne Schutte Lange to senior account executive.

Becky **BODENNER**

Former Dorland Executive Joins Dudnyk

Multichannel, healthcare communications

agency Dudnyk has named Becky Bodenner senior VP, creative director. Ms. Bodenner was most recently senior VP, chief creative officer for Dorland Global Health Communications.

Consulting **POOL**Dr. Daniel **SCHULTZ**

Former FDA Center Director Joins Greenleaf Health

Daniel Schultz, M.D., FACS, former director of the Center for Devices and Radiological Health (CDRH) at the U.S. Food and Drug Administration (FDA), has joined Greenleaf Health as senior VP, medical devices and combination products. Greenleaf is a full-service regulatory consulting firm that provides strategic guidance to companies regulated by the FDA and those developing innovative solutions to pressing public health problems around the globe.

In this new role, Dr. Schultz provides strategic consulting services and works with Greenleaf clients to bring innovative devices to patients. He is based in the firm's newly expanded Washington, D.C., office. He received a medical degree from the University of Pittsburgh and is board certified in surgery and family practice.

CRO **POOL**Dr. Herman **SCHOLTZ**

Covance Names Head of Global Clinical Pharmacology Services

Herman Scholtz, M.D., has joined global drug-development services company Covance as VP and general manager of global clinical pharmacology services.

Dr. Scholtz provides strategic leadership and operational oversight for all clinical research units, with responsibilities that include the planning and execution of clinical studies that support initial clinical investigations of drugs, chemicals, or devices, and the investigation of compounds for subsequent development.

Dr. Scholtz joins Covance from Parexel International, where he most recently served as corporate VP, early drug development, clinical research services.

He received a medical degree from the University of Pretoria and specialized in anesthesiology at the University of the Free State in Bloemfontein, South Africa.

Colin SHANNON

PRA International President Takes On CEO Role

Colin Shannon, president and chief operating officer of PRA International, has been promoted president and CEO. Mr. Shannon succeeds retiring CEO Terry Bieker. PRA International is a CRO that performs studies in all therapeutic areas, with specialization in oncology, neurosciences, respiratory/allergy, cardiovascular, and infectious diseases.

Art ZIEGLER

Prologue Appoints Business Development VP

Global oncology contract research organization Prologue has named Art Ziegler VP of business development. Mr. Ziegler brings 25 years of clinical research and business development experience to Prologue, including various positions in the pharmaceutical, biotechnology, and contract research fields.

Mr. Ziegler's primary duties at Prologue include securing levels of sustainable, profitable revenue necessary to meet the compa-

ny's financial objectives through effective sales and marketing strategies; developing and implementing marketing and sales initiatives to create awareness and demand for Prologue services within the oncology clinical research community; and identifying and meeting key decision-makers of potential clients.

Service POOL

Brian KELLY

Dr. Tracy Ken TSUETAKI

i3 Taps Group President for Three Business Units

Pharmaceutical services company i3 has named Brian Kelly group president for its i3 Innovus, i3 Drug Safety, and i3 Pharma Informatics business units. Mr. Kelly's appointment enables the existing business unit presidents of Innovus, Drug Safety, and Pharma Informatics to help drive strategic focus across the units while maintaining the distinctive brands of each.

Before joining i3, Mr. Kelly was global VP

and general manager in Covance's central laboratory services business.

In other moves, Tracy Ken Tsuetaki, O.D., has been appointed president of i3 Research. Dr. Tsuetaki also joins i3 from Covance, where he was chief marketing officer and a corporate VP. He holds a doctorate of optometry from the University of California and an MBA from Northwestern University's Kellogg School of Management.

Technology POOL

John DIBELLA

Simulations Plus Promotes Marketing Manager

Simulations Plus, a provider of simulation and modeling software to the pharmaceutical industry, has named John DiBella manager of marketing and sales. Mr. DiBella has been with Simulations Plus for more than six years, four of those in marketing and sales, and was the original developer of the company's DDDPlus simulation software program. He holds an M.S. in biomedical engineering from Case Western Reserve University. ♦

BIOPark Pavilion Showcases Innovations and Advances Products



The BIOPark Pavilion is just one exciting new feature of the 2010 BIO International Convention.

Showcasing breakthrough technologies that have the potential to heal, fuel and feed the world, the BIOPark Pavilion promises to bring innovators and investors together in a collaborative setting to discuss ways to move products from lab to marketplace.

This is a unique opportunity to:

- See new and emerging technologies
- Network in a relaxed setting
- Foster business partnerships
- Advance the commercialization of products

The 2010 BIO International Convention in Chicago will also deliver high-profile keynote speakers, education sessions focused around 17 timely tracks, the BIO Exhibition (with 1,800 companies and 6 Product Focus Zones), evening networking events and more.



FULFILLING THE PROMISE



HEAL, FUEL, FEED THE WORLD.

Follow us online:



May 3-6, 2010, Monday-Thursday
McCormick Place, Chicago, IL USA
convention.bio.org

A SERVICE OF:
Bio
BIOTECHNOLOGY
INDUSTRY ORGANIZATION